ClinicalTrials.gg
No longer availableNCT05286372Updated Nov 12, 2026

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

An expanded access record providing AMX0035 in Amyotrophic Lateral Sclerosis, sponsored by Amylyx Pharmaceuticals Inc.. No longer available at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Amylyx Pharmaceuticals Inc. · Expanded access

How we know

Updated Nov 12, 2026Now No longer availableGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Other kind
10 of 440
none open now
Registered
321st of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is one of 10 of another kind, and was the 321st registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The Expanded Access Program will provide access and assess the safety of AMX0035 for the treatment of people living with ALS.

Read the detailed description

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This Expanded Access Program is designed to provide expanded access to AMX0035 for the treatment of people living with ALS and assess safety in diverse populations/stages of ALS over 48 weeks.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, at least 18 years of age (inclusive);
  • Diagnosis of ALS made by a physician experienced with the management of ALS;
  • >36 months from symptom onset defined as first weakness
  • Capable of providing ;
  • Capable of and willing to follow program procedures.
  • Participants who have established care with a physician experienced in treating patients with ALS involved in the program and will maintain this clinical care throughout the duration of their time in the program.
  • Women of (e.g., not for at least one year or surgically sterile) must agree to use adequate for the duration of the program and 3 months after last dose of AMX0035;

    • Women must not be planning to become pregnant for the duration of the program and 3 months after last dose of study drug
  • Men must agree to practice contraception for the duration of the program and for at least 3 months after last dose of program drug;

    • Men must not plan to father a child or provide sperm

Exclusion criteria

Exclusion Criteria

  • Currently enrolled in a therapeutic study involving the use of an therapy;
  • Dependence on invasive mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at Screening;

    • No current need for tracheostomy or PAV (defined as more than 22 hours daily of mechanical ventilation for more than one week (7 days) or based on the site investigator's judgment; no need anticipated for the next 12 weeks
  • In the judgment of the Investigator, the participant's expected survival is less than 6 months
  • History of known allergy to the following: PB, bile salts, /constituents of the formulation;
  • Abnormal liver function defined as and/or ALT >3 times the (obtained within 12 weeks from first dose);
  • Renal insufficiency as defined by \<60 mL/min/1.73m2 (obtained within 12 weeks from first dose);
  • Pregnant women or women currently breastfeeding;
  • Current severe biliary disease which may result in the investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder;
  • History of Class III/IV heart failure (per - NYHA);
  • Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Site Investigator clinical judgment;
  • Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed c consent, according to Site Investigator judgment;
  • unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the program, according to Site Investigator judgment;
  • Treatment, current or within 90 days from screening with any cell therapies or gene therapies;
  • Implantation of Diaphragm Pacing System (DPS);
  • Anything that, in the opinion of the Site Investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the program;
  • Current or planned exposure to any prohibited medications listed in Section 6.8.1 of the protocol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

06

Where to request access

21 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • The Kaiser Permanente Medical Group
    Oakland, California 94612, United States
  • Nova Southeastern University
    Fort Lauderdale, Florida 32608, United States
  • Holy Cross Health
    Fort Lauderdale, Florida 33308, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • Northwestern University
    Chicago, Illinois 60614, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66103, United States
  • The Sean M. Healey & AMG Center for ALS Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Neurology Associates, P.C. / Somnos Clinical Research
    Lincoln, Nebraska 68510, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Weinberg ALS Center
    Philadelphia, Pennsylvania 19107, United States
  • Texas Tech University Health Sciences Center El Paso
    El Paso, Texas 79995, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
  • University of Washington School of Medicine
    Seattle, Washington 98195, United States
  • Providence St. Luke's Rehabilitation Medical Center
    Spokane, Washington 99202, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Hispanic Alliance for Research & Translational Research
    San Juan, 00936, Puerto Rico
07

Updates

1 registry update since Sep 25, 2026
Status
Approved for marketing→No longer available
changed Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Approved for marketing→No longer available
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT05286372
Lead sponsor
Amylyx Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Mar 18, 2022
Last update
Nov 12, 2026
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion